These findings are discussed with regard to current understanding of human immune responses to schistosomeinfection.
2
Protective immunity against human schistosomeinfection develops slowly, for reasons that are not yet fully understood.
3
Hepatic fibrosis is the main cause of increased morbidity and mortality in humans with schistosomeinfection.
4
Splenomegaly is a characteristic symptom of schistosomeinfection, and splenic abnormality may promote the progression of hepatic fibrosis.
5
Whether the treatment will impact upon the offspring's responses on exposure to primary schistosomeinfection remains to be elucidated.
6
Schistosomeinfection begins with the penetration of cercariae through healthy unbroken host skin.
7
Background: Schistosomeinfections are often clinically silent, but some individuals develop severe pathological reactions.
8
These assays and tools also have future potential for use in detection of schistosomeinfections in humans and livestock.
9
Schistosomeinfection of these patients and controls was measured by an enzyme-linked immunosorbent assay that detected circulating anodic antigen in serum.
10
However, responses to schistosomeinfections, and candidate vaccines, are likely to be different among people from endemic settings compared to schistosome-naïve Dutch volunteers.
11
The ability of the host to modulate the granulomatous response around ova trapped in tissues determines the severity of disease to schistosomeinfections.